Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) announced today that the Company will withdraw its European Marketing Authorization Application (MAA) for vosaroxin ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Sunesis Pharmaceuticals Inc. (SNSS) PT Lowered to $3 at Cantor Fitzgerald Following MAA Withdrawl May 2, 2017 6:53 AM Sunesis Pharmaceuticals Announces Withdrawal of European Marketing Authorization Application (MAA) for Vosaroxin as a Treatment for Relapsed/Refractory AMLMay 1, 2017 4:30 PM